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Risk Factors for Major Early Adverse Events Related to Cardiac
Catheterization in Children and Young Adults With Pulmonary
Hypertension: An Analysis of Data From the IMPACT (Improving Adult
and Congenital Treatment) Registry
Michael L. O’Byrne, MD, MSCE; Kevin F. Kennedy, MS; Joshua P. Kanter, MD; John T. Berger, MD; Andrew C. Glatz, MD, MSCE
Background-—Cardiac catheterization is the gold standard for assessment and follow-up of patients with pulmonary hypertension
(PH). To date, there are limited data about the factors that influence the risk of catastrophic adverse events after catheterization in
this population.
Methods and Results-—A retrospective multicenter cohort study was performed to measure risk of catastrophic adverse outcomes
after catheterization in children and young adults with PH and identify risk factors for these outcomes. All catheterizations in
children and young adults, aged 0 to 21 years, with PH at hospitals submitting data to the IMPACT (Improving Adult and Congenital
Treatment) registry between January 1, 2011, and December 31, 2015, were studied. Using mixed-effects multivariable regression,
we assessed the association between prespecified subject-, procedure-, and center-level covariates and the risk of death, cardiac
arrest, or mechanical circulatory support during or after cardiac catheterization. A total of 8111 procedures performed in 7729
subjects at 77 centers were studied. The observed risk of the composite outcome was 1.4%, and the risk of death before discharge
was 5.2%. Catheterization in prematurely born neonates and nonpremature infants was associated with increased risk of
catastrophic adverse event, as was precatheterization treatment with inotropes and lower systemic arterial saturation. Secondary
analyses demonstrated the following: (1) increasing volumes of catheterization in patients with PH were associated with reduced
risk of composite outcome (odds ratio, 0.8 per 10 procedures; P=0.002) and (2) increasing pulmonary vascular resistance and
pulmonary artery pressures were associated with increased risk (P<0.0001 for both).
Conclusions-—Young patients with PH are a high-risk population for diagnostic and interventional cardiac catheterization. Hospital
experience with PH is associated with reduced risk, independent of total catheterization case volume. ( J Am Heart Assoc.
2018;7:e008142. DOI: 10.1161/JAHA.117.008142.)
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P ulmonary hypertension (PH) affects 2.1 to 3.7 childrenper million.1–3 Despite strides in pharmacotherapy, it
remains a condition with high mortality and morbidity. Right-
sided heart catheterization remains the gold standard tool for
diagnosis, classification, risk stratification, and longitudinal
follow-up of these patients.4 Right-sided heart catheterization
is technically straightforward and ranked in the lowest risk
stratum of procedural risk hierarchies.5–7 However, patients
with PH may be less stable than other children during
induction of anesthesia, the procedure itself, and during
recovery from anesthesia, with a resultant increase in the risk
of catheterization-associated catastrophic adverse outcomes.
Elevated pulmonary artery (PA) pressure or indexed
pulmonary vascular resistance (PVRI) are both components
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of all 3 published risk adjustment/risk prediction scores.5,6,8
However, there is controversy about the magnitude of risk
associated with heart-sided catheterization in patients with
PH.9 The risks of a catastrophic outcome with a catheteriza-
tion vary widely, from 0% to 5.3%, depending on whether they
are derived from single-center case series,10–13 PH-specific
clinical registries,14,15 multicenter registries of cardiac
catheterization,16 or administrative databases.17,18
Measurement of risk is challenging because of the broad
spectrum of disease severity, range of comorbid conditions,
and relatively small individual hospital volumes. Attempts
have been made to overcome these challenges with clinical
registries14,15 and with administrative databases.17,18 Dis-
ease-specific registries, like the Tracking Outcomes in Pedi-
atric Pulmonary Hypertension registry, can record clinically
detailed information about a cohort of subjects. Expense and
logistical complexity, however, limit their size and the scope
of analyses possible. In addition, requirements for patient
consent to participate introduce the possibility of recruitment
bias. In contrast, administrative databases, such as the
Pediatric Health Information System (PHIS), contain data on
all patients treated at member hospitals. This allows for the
expedient collection of information about the entire popula-
tion at risk at many hospitals. These same studies are limited
by clinical data that are not included in administrative
databases (eg, hemodynamic data and detailed information
about cardiac diagnoses and specific interventions). We
sought to overcome these limitations by using data from
the IMPACT (Improving Adult and Congenital Treatment)
registry, a multicenter clinical registry of catheterizations in
patients performed at both primary pediatric and general
hospitals in the United States. The IMPACT registry includes
detailed clinical, hemodynamic, and procedural data on all
catheterization procedures at contributing hospitals, providing
a representative study sample of patients with PH undergoing
catheterization. We performed a retrospective cohort study
using data from the IMPACT registry to more accurately
measure the risk of catastrophic adverse event during or after
catheterization in this population and to identify risk factors
for major adverse events. We also performed secondary
analyses to assess whether (1) severity of PH (measured by
PA pressure, PVRI, or cardiac index) and (2) procedural
volume (PH-specific catheterization and total catheterization
volume) influenced risk of catastrophic adverse events.
Methods
Data Source
The IMPACT registry is a clinical registry funded by the
American College of Cardiology Foundation and managed by
the National Cardiovascular Data Registry, with data from 88
pediatric and general hospitals performing cardiac catheter-
izations in children and adults with congenital heart disease
at the time of this analysis. Participating centers collect
information on all patients undergoing cardiac catheteriza-
tion, including patient demographics, medical/surgical his-
tory, procedural information, and adverse events through
hospital discharge. Data are recorded using standardized
data elements and definitions. The database is subject to
rigorous quality assurance standards.19 Auditing procedures
are still being developed.19–21 The current study used data
from IMPACT v1.0.1. Analysis was performed on deidentified
data and, as such, does not represent human subjects
research in accordance with the Common Rule (45 CFR
46.102[f]). Data, analytic methods, and study materials will
not be made available to other researchers for the purposes
of reproducing the results or replicating the procedure,
because this is not consistent with the data-use agreement
between study staff and the American College of Cardiology
Foundation and the National Cardiovascular Data Registry.
Study Population and Study Procedures
The study population was identified by direct query of the
IMPACT registry by analysts at the Mid America Heart
Institute. It included subjects from birth until 21 years of
age who underwent procedures recorded in the IMPACT
registry between January 1, 2011, and December 31, 2015.
The subjects had PH identified by IMPACT registry code (1400
for primary PH, 1385 for pulmonary vascular obstructive
disease, and 1390 for pulmonary vascular obstructive disease
[Eisenmenger]) or met the hemodynamic definition of PH from
Clinical Perspective
What Is New?
• This study is the first cohort study of children and
adolescents with pulmonary hypertension undergoing car-
diac catheterization with a representative national sample of
real-world practice, evaluating both the risk of catastrophic
adverse outcome and factors influencing them.
What Are the Clinical Implications?
• The study provides a new accurate estimate of the risk of
catheterization in this population, which is important for
preprocedural evaluation of risk and benefit.
• This study also demonstrates a significant association
between larger pulmonary hypertension case volume and
lower risk of catastrophic adverse event, which should
motivate research into whether the benefits seen at large
centers are attributable to transmissible best practices or
are intrinsic results of scale.
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2015 American Heart Association/American Thoracic Society
Pediatric Guidelines4 (ie, mean PA pressure, ≥25 mm Hg).
Patients with elevated PA pressure were excluded if they had
a ratio of pulmonary/systemic blood flow >1.5:1 and PVRI
<4 WU/m2, because their PA pressures reflected appropriate
hemodynamics in the face of a significant left-to-right shunt
rather than pulmonary vascular disease. To improve the
sensitivity of our cohort ascertainment, we also included
subjects whose PA pressure was missing and whose PVRI was
≥4 WU/m2. Patients were excluded if they were undergoing
PA balloon or stent angioplasty, to avoid contamination of the
study sample with patients based on elevated main PA
pressure that was the result of fixed anatomic stenosis.
Similarly, patients undergoing isolated balloon valvuloplasty of
either the pulmonary or aortic valves were also excluded.
Procedures from centers submitting data for <6 months,
procedures from centers performing <10 total PH catheter-
izations were excluded, extracorporeal membrane oxygena-
tion (ECMO) or left ventricular assist device were in use before
the case. Finally, cases in patients with single-ventricle heart
disease were excluded.
Data collected included demographics, medical history
(including preprocedure risk factors), hemodynamic data, and
details of the procedure (specific interventions, anesthesia at
start of the case, device used, and presence of a trainee).
Outcomes of interest were mortality and major adverse
events (cardiac arrest, new arrhythmia, new heart valve
regurgitation, tamponade, air embolus, initiation of dialysis,
embolic stroke, new ECMO, new ventricular assist device,
unplanned cardiac, vascular, or other surgery, vascular
complication requiring treatment, and repeated catheteriza-
tion, all before discharge). Death in the IMPACT registry is
coded as death before discharge. For death, the date of death
is recorded. For other adverse outcomes, any event before
discharge within 30 days is recorded.
Cause of PH was divided between the following:
(1) idiopathic PH (IPAH), (2) PH associated with congenital
heart disease, (3) PH with cardiomyopathy, (4) PH after
orthotopic heart transplant, and (5) pulmonary vein stenosis
and PH. Diagnoses were based on IMPACT codes recorded in
the registry. Preprocedure medications are recorded in the
IMPACT registry by 1 of 8 predefined drug classes (diuretics,
antiarrhythmics, antihypertensives, antiplatelet agents, anti-
coagulants, b blockers, vasodilators, and inotropes). There is
significant class overlap, because pulmonary vasodilators
(inhaled NO, phosphodiesterase-5 inhibitors, prostacyclin
analogues, calcium channel blockers, and endothelin receptor
antagonists) can fall into several of these groups or may not
be recorded at all. No field in the registry records the specific
medications received; thus, there are no means of identifying
specific medications or numbers of medications within a
class.
Statistical Analysis
Standard descriptive statistics were calculated. Continuous
variables were expressed as meanSD or median (range and
interquartile range [IQR]). Categorical variables were
described as proportions and counts. Multiple catheterization
procedures were performed on individual subjects during the
study period. All eligible procedures were included, and all
statistics are reported per procedure, except where noted.
The primary outcome was a composite outcome (catas-
trophic adverse outcome) composed of death on the day of
catheterization or the day after catheterization and cardiac
arrest or initiation of ECMO. Because it is not possible to
assess the attributability of these events to the catheteriza-
tion retrospectively in a multicenter registry, we restricted the
time horizon for adverse events to improve attributability, as
previous described.17,18 ECMO and cardiac arrest in the
IMPACT registry data dictionary measure ECMO or cardiac
arrest within 30 days. Unlike death, there is no date attached
to these outcomes in the registry. We studied the time
distribution of these events to determine the time course of
events after these events. For patients with cardiac arrest,
>50% died or were discharged within 10 days of catheteri-
zation, suggesting a temporal association between the event
and the catheterization. A similar analysis is less productive in
the case of ECMO, which prolongs life, so it was not
performed.
The goal of the primary analysis was to generate an
estimate of the risk of catastrophic adverse event with
appropriate adjustment for patient- and procedure-level
factors. As such, no primary exposure was defined before
analysis. All covariates were specified before analysis on the
basis of previous studies and clinical suspicion: age group
(with interaction for prematurity), cause of PH, genetic
syndrome, cardiac operation in past 30 days, mechanical
ventilation, renal insufficiency, precatheterization inotropes,
precatheterization vasodilators, and interventional procedure
performed during the procedure. The IMPACT registry has a
validated procedural risk-adjustment model,5 which includes
procedure-risk categories. These were not used because the
IMPACT procedure-risk categories combine patient age and
specific procedure, which makes evaluation of their relative
contribution impossible in subsequent analysis. Instead, the
performance of a transcatheter intervention was recorded. No
additional forward or backward selection was used to refine
the model. Hierarchical logistic regression was used to
analyze outcomes, with a random intercept for center
included to account for clustering by hospital.
Analyses of risk factors for the secondary outcomes were
performed similarly. Two additional prespecified analyses
were performed, adding factors to our initial model:
(1) assessing whether the addition of mean PA pressure,
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PVRI, or cardiac index influenced risk of the primary outcome;
and (2) center annual catheterization procedural volume and
center annual PH catheterization volume. For the latter, a
model was calculated including PVRI to provide the best case-
mix adjustment; another model was calculated without PVRI.
Hemodynamic parameters indicative of right ventricular
diastolic and systolic dysfunction (eg, right atrial mean
pressure or right ventricular end-diastolic pressure) are not
recorded in the current iteration of the IMPACT registry, and
so could not be used in these analyses. To evaluate whether
assumptions about covariance in the chosen modeling
strategy biased results, generalized estimating equation mod-
els for the primary risk model were calculated, with no
significant differences in the point estimates and confidence
intervals (CIs) relative to the mixed-effects model (Table S1).
A potential source of bias is inclusion of multiple
catheterization procedures per individual patient. Patients
undergo multiple catheterizations in some cases because of
concern for severe disease, while at the same time having
undergone multiple catheterizations is suggestive that the
patient has not experienced a catastrophic adverse outcome
with previous catheterizations. To assess whether inclusion of
multiple catheterizations introduced significant bias, a sensi-
tivity analysis was performed that restricted analysis to the
first catheterization performed in each subject. As for the
primary model, an analogous generalized estimating equa-
tion model was calculated for first catheterizations (data not
shown).
Missing data were rare (<1% of cases). Therefore, case
elimination/restriction was used, with analysis restricted to
cases with complete data. No imputation was applied.
A threshold for statistical significance was set at P<0.05.
All data analysis was performed using SAS 9.4 (SAS Institute
Inc, Cary, NC).
Results
Study Population
Between January 1, 2011, and December 31, 2015, 14 636
procedures meeting diagnostic criteria for PH were performed
in 11 247 individual patients at 88 hospitals (Figure 1). Of
these cases, 1798 procedures were excluded because the
subject was >21 years of age, 135 procedures were excluded
because the patient was receiving ECMO, 32 procedures were
excluded because the patient was using a left ventricular
assist device, 1214 cases were excluded because the patient
had a single-ventricle physiological feature, and 1765 cases
were excluded because the pulmonary/systemic blood flow
ratio was >1.5:1 and the PVRI was <4 WU/m2. A total of
Figure 1. Study population. BAV indicates balloon aortic valvuloplasty; BPV, balloon pulmonary
valvuloplasty; ECMO, extracorporeal membrane oxygenation; PA, pulmonary artery; PVRI, indexed
pulmonary vascular resistance; Qp:Qs, ratio of pulmonary/systemic blood flow; and VAD, ventricular
assist device.
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1540 cases for PA stent or balloon angioplasty, aortic
valvuloplasty, and pulmonary valvuloplasty were excluded.
Excluding these cases removed all the cases from 5 hospitals.
An additional 6 hospitals (and 25 cases) were excluded
because of <10 procedures during the study period. The
resulting analytic cohort included 8111 procedures performed
in 7729 patients at 77 hospitals. This represents 10.5%
(9010/77 116) of all procedures in the IMPACT registry
during the study period.
Median age at catheterization was 3 years (IQR, 0–
12 years) (Table 1). Of catheterizations, 51% were performed
in subjects who were men and 64% in white subjects. In terms
of diagnosis, 26% occurred in subjects with IPAH, 45%
occurred in those with PH associated with congenital heart
disease, 17% occurred in those with PH after an orthotopic
heart transplant, 7% occurred in those with PH and cardiomy-
opathy, and 6% occurred in those with pulmonary vein
pathology. A history of chronic lung disease was present in
21% of subjects. Renal insufficiency was known in 4.2% of
subjects. Before catheterization, 21% received antihyperten-
sive medications (including calcium channel blockers), 25%
received vasodilators, and 12% received inotropes. Of the
total cases, 14% were mechanically ventilated before the pro-
cedure; 2.6% had undergone a cardiac operation in the
30 days before catheterization.
General anesthesia was used in 85% of cases (Table 2). Of
the total cases, 62% were intubated at the start of the case,
10% were previously intubated, 8% received a laryngeal mask
airway, and 4% had a previous tracheostomy. Of procedures,
26% included a transcatheter intervention (Table 3).
Mean cardiac index was 3.81.4 L/min per m2. Median
PVRI was 4.1 WU/m2 (IQR, 2.6–6.5 WU/m2), with 67% of
cases performed in subjects with PVRI >3 WU/m2. Hemody-
namic vulnerability was present in 76% of subjects, 55% if
excluding PVRI.
Outcomes
Observed risk of catastrophic event was 1.4% (95% CI, 1.2%–
1.7%) (Table 4). The risk of death in the catheterization
laboratory was 0.1%, the risk of cardiac arrest was 1.2%,
initiation of ECMO was 0.4%, and death within 1 day of
catheterization was 0.4%. Observed risk of death before
discharge was 5.2%. The risk of any major adverse event,
excluding death, was 5.0%. Including death before discharge,
the risk was 9.1%. The median postprocedure hospital length
of stay was 1.0 day (IQR, 0–10 days).
Multivariable Model
A multivariable model was calculated to assess the associ-
ation between patient-level characteristics and risk of
catastrophic adverse event (Figure 2). The odds ratio (OR)
for catastrophic adverse event was greater in premature
neonates (OR, 3.89; 95% CI, 1.17–12.89; P=0.03) and infants
without prematurity (OR, 1.72; 95% CI, 1.04–2.83; P=0.03)
than in subjects between 1 and 8 years old. The receipt of
inotropes before the procedure was associated with increased
risk (OR, 7.23; 95% CI, 4.77–10.96; P<0.0001). Increasing
systemic arterial saturation was associated with a lower OR
(OR, 0.81 per 5% change; 95% CI, 0.74–0.89; P<0.0001).
Using conditional standardization, the risk of catastrophic
adverse event in a patient with idiopathic pulmonary arterial
hypertension between 1 and 8 years old, with no additional
risk factors, is 0.9%.
A sensitivity analysis was performed that restricted cases
to the first catheterization for each individual patient
(Table S2). There were no significant changes in the observed
association between risk factors and outcome, supporting the
notion that including multiple catheterizations for individual
subjects did not bias results.
Severity of PH and Risk
The associations between risk of composite outcome and 3
hemodynamic markers (mean PA pressure, PVRI, and cardiac
index) were evaluated in separate models (Tables S3 through
S5). Increasing PA pressure (OR, 1.21 per 10 mm Hg; 95% CI,
1.11–1.32 per 10 mm Hg; P<0.0001) and PVRI (OR, 1.08 per
1 WU/m2; 95% CI, 1.05–1.11 per 1 WU/m2; P<0.0001) were
both associated with a higher OR for catastrophic adverse
event, whereas a higher cardiac index was associated with a
lower OR for catastrophic adverse event (OR, 0.75 per 1 L/
min per m2 increase; 95% CI, 0.63–0.90 per 1 L/min per m2
increase; P=0.002).
Effect of Procedural Volume
In the study sample, the median annual hospital total
catheterization volume was 266 cases (IQR, 145–445 cases).
For the same sample, the median number of PH cases each
year was 25 (IQR, 15–47). The median proportion of
catheterizations performed in subjects with PH was 10%
(IQR, 9%–12%; range, 4%–21%). For each center, the number
of catheterizations in subjects with PH was proportional to the
total number of catheterizations performed and correlated
significantly to the total catheterization volume, although
there remains significant variation between centers (b, 0.16;
P<0.0001; r2=0.86; Figure 3).
To assess whether procedural volume affected the risk of
catastrophic adverse event, a secondary analysis was per-
formed, adding the total catheterization and PH catheteriza-
tion volumes to the model including PVRI (Table S6).
Increasing annual PH volume was associated with a lower
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OR for catastrophic adverse event (OR, 0.84; 95% CI, 0.75–
0.94; P=0.002). In the same model, increasing annual
catheterization volume was associated with a higher OR of
catastrophic adverse event (OR, 1.16; 95% CI, 1.04–1.30;
P=0.007). The addition of these factors to the model does not
affect the previously observed associations between risk
factors and risk of catastrophic event. An additional model
without PVRI included (but also including procedural volumes)
was also calculated (Table S7), in which point estimates for
coefficients and CIs did not differ significantly.
Discussion
This multicenter, retrospective, cohort study investigated the
risk of catastrophic adverse events during and after cardiac
catheterization in children and adolescents with PH. The
observed risk of catastrophic adverse event (death, cardiac
arrest, or initiation of ECMO) was 1.4%. To adjust for the
specific case mix of this study, we also calculated an
estimated risk (adjusting for known confounders and stan-
dardized for a school-aged child with IPAH), which was 0.9%.
Both the observed and estimated risks for catastrophic
adverse events are many-fold higher than those measured in
single-center case series12,13 and catheterization registries.16
However, they are consistent with the much higher risks
reported in recent studies using either administrative18 or
Table 1. Study Population
Variable Value
No. of catheterization procedures 8111
No. of individual patients 7729
No. of sites 77
Age, mean (IQR), y 3 (0–12)
Age category
Neonate with prematurity 0.6 (47)
Neonate without prematurity 2.7 (222)
Infant with prematurity 9.6 (780)
Infant without prematurity 14.3 (1162)
1–8 y 37.9 (3072)
8–18 y 30.2 (2453)
>18 y 4.6 (375)
Female sex 50 (4037)
Race
White 64 (5194)
Black 21 (1692)
Asian 5 (437)
Other 10 (788)
Weight, mean (IQR), kg 14.6 (7.1–41.7)
Diagnosis
APAH-CHD 45 (3615)
IPAH 26 (2135)
Status after OHT 17 (1339)
Cardiomyopathy 7 (553)
PV stenosis 6 (469)
Genetic syndrome
None 87 (7061)
Alagille syndrome 0.4 (36)
22q11.2 Microdeletion syndrome 3 (241)
Trisomy 21 8 (674)
Williams-Beuren syndrome 0.5 (41)
Other genetic syndrome 0.7 (58)
Chronic lung disease 21 (1713)
Congenital diaphragmatic hernia 1.8 (143)
Renal insufficiency 4.2 (341)
Coagulation disorder 1.5 (120)
Diabetes mellitus 1.5 (123)
Hepatic disease 2.0 (164)
Seizure disorder 3.5 (279)
Sickle-cell anemia 0.5 (43)
Mechanical ventilation
before catheterization
14 (1173)
Continued
Table 1. Continued
Variable Value
Medications before catheterization
Antiarrhythmic 6 (512)
Anticoagulation 10 (773)
Antihypertensive 21 (1721)
Antiplatelet 21 (1695)
b Blocker 7 (585)
Diuretics 43 (3510)
Pressors 12 (1005)
Vasodilators 25 (2049)
Case status
Elective 80 (6452)
Urgent 18 (1444)
Emergency 2 (150)
Salvage 0.1 (11)
Cardiothoracic operation in prior 30 d 3 (210)
Data are given as percentage (number) unless otherwise indicated. APAH-CHD indicates
pulmonary hypertension associated with congenital heart disease; IPAH, idiopathic
pulmonary arterial hypertension; IQR, interquartile range; OHT, orthotopic heart
transplantation; and PV, pulmonary vein.
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clinical registry data.15 There is no controversy about the
importance of hemodynamic evaluation in patients with PH,
but data from these studies reiterate the risks associated with
catheterization in this population and the potential benefit of
identifying modifiable risk factors for an adverse event.
To our knowledge, the largest cohort study of pediatric
patients with PH undergoing catheterization is the Tracking
Outcomes in Pediatric Pulmonary Hypertension registry,
which includes data from 908 catheterizations in 472
individual patients treated between January 2018 and Febru-
ary 2012 at 31 centers in 19 countries. The observed risk of
catastrophic adverse event (cardiac arrest, ECMO, or
catheterization-associated death) in this population was
between 0.6% and 1.7%.15 General anesthesia was identified
as highly correlated with adverse events. However, the low
total number of events makes statistical adjustment impos-
sible. This is important because it is not possible to adjust for
case mix, which is especially relevant in this cohort, in whom
the median PVRI was 15.5 WU/m2, and because it is not
possible to explore what factors influence the risk of adverse
events. A contemporaneous study using administrative data
from the PHIS database generated a larger study population
and allowed for risk adjustment and the identification of
factors associated with adverse events.18 In this study, being
a premature neonate, PH after heart transplantation, and
preprocedure systemic vasodilators or hemodialysis were
associated with increased risk of catastrophic event, whereas
receipt of pulmonary vasodilators before catheterization and
age 8 to 18 years were associated with decreased risk. A
clear limitation of studies using administrative data is that not
all potentially relevant clinical information is included in the
registry. For example, there are no hemodynamic (pressure or
oximetry) data included in PHIS, and there are limited data
about specific cardiac diagnoses and procedures.
The current study addresses these concerns. The IMPACT
registry was designed to capture the characteristics of
patients undergoing catheterization and the procedures
themselves. As a result, it contains much greater detail about
patient and procedural factors that potentially influence
periprocedural risk and has defined fields to capture hemo-
dynamic data.5 This allowed for us to evaluate risk factors in
light of more accurate clinical data and to potentially explore
the role of hemodynamics. In the current study, younger
patient age (premature neonates and infants without
Table 2. Procedure Characteristics
Characteristics Value
Transcatheter intervention 26 (2114)
Procedure risk category
1 58 (4692)
2 27 (2154)
3 7 (536)
4 9 (728)
Sedation/anesthetic strategy
General anesthesia 85 (6855)
Sedation 14 (1141)
None 1 (70)
Missing/other 0.6 (45)
Airway strategy
Endotracheal intubation (before case) 10 (828)
Endotracheal intubation (at start of case) 62 (5059)
Laryngeal mask airway 8 (685)
Spontaneous breathing 15 (1213)
Tracheostomy 4 (345)
CPAP/bag mask ventilation 0.2 (13)
Trainee present 68 (5479)
Hemodynamics
Cardiac index, L/min per m2 3.81.4
Mixed venous saturation, % 6710
Systemic arterial saturation, % 937
PVRI, mean (IQR), WU/m2 (n=7593) 4.1 (2.6–6.6)
PA pressure mean, mm Hg 33.09.1
Systemic ventricular end-diastolic pressure, mmHg 13.56.5
Hemodynamic vulnerability (ANY) 77 (6274)
MV saturation <60% 21 (1612)
Systemic arterial saturation <95% 43 (3274)
Systemic ventricular EDP >18 mmHg 22 (1146)
PVRI >3 WU/m2 67 (4493)
Hemodynamic vulnerability (excluding PVRI) 55 (4430)
Data are given as percentage (number) or meanSD, unless otherwise indicated. CPAP
indicates continuous positive airway pressure; EDP, end-diastolic pressure; IQR,
interquartile range; MV, mixed venous; PA, pulmonary artery; and PVRI, indexed
pulmonary vascular resistance.
Table 3. Transcatheter Interventions
Procedure
Value
(N=2097)
Closure of patent ductus arteriosus 26 (553)
Pulmonary vein balloon angioplasty 16 (339)
Pulmonary vein stent angioplasty 4 (92)
Creation/augmentation of an atrial septal communication 8 (161)
Angioplasty of coarctation (with or without stent) 5 (107)
Closure of atrial septal defect 5 (104)
Transcatheter pulmonary valve replacement 2 (51)
Other procedures 33 (690)
Data are given as percentage (number). In some cases, >1 intervention was performed.
These interventions are listed separately.
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prematurity relative to older patients) was associated with
higher risk of catastrophic adverse event, as was the receipt
of inotropic medications before catheterization. More impor-
tant, the use of a clinical registry of patients undergoing
catheterization produced a large sample of patients with a
broad range of diagnoses, severity of disease (evinced by the
range of PVRI), and comorbid conditions. Thus, the estimated
risk from this sample (the risk calculated for a patient with
median age and no other comorbidities) is representative of
the “real-world” risk associated with cardiac catheterization of
a standard-risk patient with PH.
Two secondary analyses were performed. The first aimed
to assess whether disease severity affected the risk of
adverse event. The initial model was established to assess
preprocedural risk factors, and the only hemodynamic
measure was oxygen saturation. However, determining how
hemodynamic measures of severity of disease affected risk of
adverse event was clearly important. To accomplish this, in
secondary analyses, PA pressure, PVRI, and cardiac index
were each added to the primary model. They were added in
separate models because of likely colinearity. Increasing
magnitude of either PA pressure or PVRI was associated with
increased risk of catastrophic adverse event, whereas
increasing cardiac output was associated with reduced risk.
To our knowledge, previous studies have not had sufficient
statistical power to assess the association between disease
severity and risk of adverse events with catheterization.
Identification of cut points where increasing risk accelerates
would allow for identification of a higher-risk stratum of
patients and direction of additional resources to these
patients. However, the total number of events in the study
sample was too small to apply splines or other methods to
assess for these cut points, highlighting the importance of
continued accrual of large observational data sets to refine
our understanding of the relationship between severity of
illness and risk of catastrophic adverse event.
Next, the degree to which hospital catheterization expe-
rience (both in terms of total catheterization volume and
volume of patients with PH specifically) influenced risk of
catastrophic event was studied. Procedural volume has been
associated with reduced risk of adverse event in the catheter-
ization of children across a broad range of diagnoses.17,22 In
previous studies of catheterization of patients with PH, the
study samples were too small (both in terms of the number of
patients and hospitals) to perform an analysis adjusted for
case-mix, but in a study using PHIS data, the observed rate of
catastrophic adverse events was higher in low-volume centers
than in higher-volume centers.18 In the current study, experi-
ence with catheterization of patients with PH (as reflected in
average PH catheterizations per year) was associated with
reduced risk of catastrophic adverse event, independent of total
catheterization volume and of PVRI and other patient factors. It
is important to acknowledge that the increased PH volume
represents the experience of the entire care team. This includes
not only the interventional cardiologist but also catheterization
laboratory staff, anesthesiologists, specialists in PH, critical
care physicians, and nursing. It is not possible to retrospectively
determine if the differences in event are attributable to
transmissible best practices (at any of these levels of the
healthcare team) or an intrinsic benefit of increased procedural
volume. An important next step is to explore these differences
in future studies. This is relevant because disseminating best
practices and/or centralizing care of these patients may be
challenging, but these factors are much more modifiable than
intrinsic patient characteristics.
The IMPACT registry is well suited to generating a
representative study sample, which is a complementary data
source to clinical registries. First, the IMPACT registry
includes data from a broad range of hospitals across the
United States, including primary pediatric and general hospi-
tals of all sizes. Disease-specific registries, on the other hand,
are more likely to be based in centers of excellence. Second,
at a patient level, consent is not required for inclusion in the
IMPACT registry, and all consecutive cases are included.
Table 4. Outcomes
Outcomes Value, % (n) 95% CI
Catastrophic adverse event
(cardiac arrest, ECMO, death
within 1 d of catheterization)
1.4 (114) 1.2–1.7
Death in laboratory 0.1 (10) 0.06–0.2
Cardiac arrest 1.2 (95) 0.9–1.4
Initiation of ECMO 0.4 (36) 0.3–0.6
Death within 1 d of catheterization 0.4 (33) 0.3–0.6
Death before discharge 5.2 (460) 4.7–5.7
Arrhythmia receiving cardioversion 0.6 (51) 0.5–0.8
Arrhythmia receiving medication 1.2 (115) 1.0–1.4
Arrhythmia receiving temporary
pacemaker
0.2 (19) 0.1–0.4
Tamponade 0.2 (14) 0.1–0.3
New dialysis 0.1 (8) 0.04–0.2
Unplanned cardiac surgery 0.4 (30) 0.2–0.5
Unplanned other surgery 0.4 (31) 0.3–0.5
Repeated catheterization 0.4 (29) 0.2–0.5
Any major adverse event, except death 5.0 (407) 4.6–5.5
Any major adverse event, including death 9.1 (742) 8.5–9.8
Hospital length of stay, mean (IQR), d 1.0 (0–10) NA
Outcomes occurring in <0.1% of cases included air embolus (n=1), new heart valve
regurgitation (n=2), initiation of ventricular assist device (n=2), unplanned vascular
surgery (n=2), and embolic stroke (n=3). CI indicates confidence interval; ECMO,
extracorporeal membrane oxygenation; and IQR, interquartile range.
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Registries requiring consent are at risk for recruitment bias.
Third, disease-specific registries may overemphasize a speci-
fic form of the disease. In PH-specific studies, this is manifest
as overrepresentation of patients with IPAH in disease-
specific studies. In large single-center series from PH centers
and PH-specific registries, patients with IPAH represent 46%
to 48% of procedures.12,14,15,23 Studies that collect all
catheterizations at a broad range of centers without consent
have much lower prevalence of IPAH and with increased
proportion of PH associated with congenital heart disease.
This is seen in the current study, in which IPAH is less than a
quarter of cases, and in studies using data from the PHIS
database18 and the Mid-Atlantic Group of Interventional
Cardiology collaborative clinical registry.16 PH centers likely
see a larger proportion of patients with IPAH than other
centers. This highlights that PH associated with congenital
heart disease represents a larger proportion of the population
at risk across the country and that this population is
potentially underrepresented in previous PH studies. There-
fore, IMPACT and disease-specific registries fulfill comple-
mentary roles, with the IMPACT registry providing a
representative national sample of broad practice, whereas
disease-specific registries, such as the Tracking Outcomes in
Pediatric Pulmonary Hypertension registry, summarize the
results of elite centers in a narrower band of potentially
severely ill patients.
An important potential modifiable factor for the safety of
patients with PH undergoing cardiac catheterization is phar-
macotherapy with pulmonary vasodilators. Medication has
improved the survival of patients with PH. In our previous study
using data from PHIS, patients receiving pulmonary vasodila-
tors had a reduced risk of catastrophic adverse events with
catheterization.18 Although current recommendations are to
pursue catheterization at diagnosis to test reactivity and
Figure 2. Risk factors for catastrophic adverse outcome. The figure is a forest plot that depicts the association between individual
prespecified patient- and procedure-level factors potentially associated with the risk of death, cardiac arrest, or initiation of extracorporeal
membrane oxygenation after catheterization in the study population. Odds ratios (ORs; blue diamonds) and 95% confidence intervals (CIs;
brackets) are depicted from the mixed-effects multivariable model. For factors associated with increased risk of the composite outcome, the
point estimate and 95% CI are completely to the right of the dashed line, marking an OR of 1. For factors associated with decreased risk of the
composite outcome, the point estimate and 95% CI are entirely to the left of the dashed line. Factors with significant association to catastrophic
adverse outcomes are boldfaced. AE indicated adverse event; APAH-CHD, pulmonary hypertension associated with congenital heart disease; CT,
computed tomography; and IPAH, primary pulmonary hypertension.
DOI: 10.1161/JAHA.117.008142 Journal of the American Heart Association 9
Pediatric Pulmonary Hypertension Catheterization O’Byrne et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 12, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
guide therapy,4 there may be patients in whom initiating
treatment before catheterization might mitigate risk without
inducing harm. This has to be balanced against the potential
risk of treatment without understanding the patient’s phys-
iological characteristics. We had hoped to further assess this
association, but the current version of the IMPACT registry
does not record specific preprocedural medications. Instead,
medications are recorded according to 8 predefined cate-
gories (inotropes, vasodilators, antiarrhythmics, antiplatelet
agents, anticoagulants, diuretics, b blockers, and blood
pressure medications). There is no category for pulmonary
vasodilators, and there is, thus, risk for omission or
misclassification of these medications, making analysis of
them impossible in this study. As the IMPACT registry
matures and undergoes serial revision, inclusion of more
detailed records of precatheterization medications would
provide a more flexible structure for asking and answering
clinically relevant questions. A potential work-around for this
obstacle would be to create a link between the IMPACT
registry and an administrative data set, such as PHIS, as has
been modeled previously.24 This leverages the strengths of
both data sets, combining the detailed clinical information
present in the former with detailed information about the use
of medications25,26 and other resources, including economic
cost,27 that are contained in the latter.
An important limitation to this study and observational
studies in general is that they are limited in their scope to the
current range of practice. Unless a practice is widespread and
distributed across risk categories with sufficient overlap, it is
not possible to determine if it affects outcome. The method
chosen for airway management is an important practice in
children with PH. Hypoventilation and resultant hypercarbia
can precipitate a life-threatening pulmonary hypertensive
crisis. Whether this is more likely with general anesthesia
(with risks during induction and recovery) or with free
breathing (with risk of respiratory suppression during the
procedure, along with the potential for hemodynamic/auto-
nomic instability) is not clear. In a prior study, use of general
anesthesia had been associated with increased risk of
adverse outcome.15 In the current study, >80% of subjects
had received anesthesia with positive pressure ventilation
during the procedure. This preponderance makes statistical
evaluation of other methods challenging. Moreover, it is also
highly likely that individual choices of airway management
were also determined by the care team and may correlate
with preprocedural risk assessment (which would further
contaminate any analyses). Without a broader range of
practice, it is challenging to make inferences on the basis
of the current data.
An important aspect of this study is that it reflects the
burden of PH in a representative national sample of
catheterization laboratories in the United States. When
compared with PH-specific disease registries, such as the
Tracking Outcomes in Pediatric Pulmonary Hypertension
registry,14,15 the mean PVRI and positive airway pressure
are lower than in registries based in hospitals specializing in
the care of patients with PH. This underscores both the
excellent results of these centers in performing many
catheterizations in severely ill patients and the importance
of identifying the practices that enable them to do this. At the
same time, the fact that the study sample includes many
patients with relatively mild disease also means that the
observed risk of major adverse events is a low-bound
estimate.
There are several additional limitations to this study.
First, the study is an observational study of current practice
of patients undergoing catheterization. There is no means of
identifying patients with prevalent PH who do not undergo
catheterization, although it is not clear what the case mix of
this population is relative to those who are undergoing
catheterization. Also, in an observational study, one cannot
infer causation from observed associations. In addition, the
causes of PH are not recorded directly in the IMPACT
registry in all cases. As described in the Methods section,
these distinctions were made using a combination of
diagnostic codes and hemodynamic data. This also compli-
cates interpretation of the association between systemic
Figure 3. Relationship between hospital annual catheterization
volume and annual volume of catheterizations performed in
patients with pulmonary hypertension. The figure is a scatter plot
of the average procedural volume for each hospital during the
study period (each blue circle represents a contributing hospital).
The total catheterization volume for each hospital is depicted on
the x axis, and the number of cases performed per year in patients
with pulmonary hypertension is depicted on the y axis. A line of
best fit is plotted as well (red). Catheterizations performed in
patients with pulmonary hypertension (PH) are a consistent
proportion of total cases (P<0.0001 and r2=0.86). PH catheter-
izations=0.159total catheterizations15.
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arterial saturation and the risk of adverse outcome. Also,
the study population contains a larger proportion of patients
with PH associated with congenital heart disease than with
chronic lung disease, but we do not have the ability to
determine if desaturation attributable to lung disease and
that from right-to-left shunt is equally associated with
adverse outcome. Third, attributing even catastrophic
adverse outcomes in sick patients to the catheterization is
challenging.17,18,28 Restriction of the primary outcome to
unequivocal events that might be plausibly related to PH
was performed. In addition, where possible, the time horizon
was limited to improve the attributability. Finally, subjects in
this series underwent multiple catheterizations. This poses 2
problems. First, patients can undergo multiple catheteriza-
tions either by routine or because of increased severity of
illness. Second, and more important, in an analysis in which
the outcome is a catastrophic adverse outcome, patients
who undergo multiple catheterizations do not face the
same risk at each catheterization. By definition, they have
not died at previous catheterizations. As in previous
analyses,17,18,22 we performed a sensitivity analysis
restricted to the initial catheterization to demonstrate that
the inclusion of repeated catheterizations did not bias our
results significantly.
Conclusion
Despite these limitations, we conclude that catheterization in
children with PH demonstrated a relatively high risk of
catastrophic adverse outcome. Risk is proportional to the
severity of pulmonary vascular disease. Experience with
catheterization in patients with PH was associated with a
reduced risk. Further research is necessary to evaluate
whether this association is attributable to transmissible best
practices or an intrinsic result of procedural volume.
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Covariate OR 95% CI 
Age category   
Neonate with prematurity 4.35  2.04-9.29 
Neonate without prematurity 0.74 0.28-1.98 
Infant with prematurity 1.16 0.53-2.53 
Infant without prematurity 1.74 1.08-2.83 
1-8 years 1 n/a 
8-18 years  0.85 0.41-1.79 
>18 years 0.24 0.03-1.76 
Diagnosis   
IPAH  1 n/a 
APAH-CHD 0.87 0.52-1.47 
Status post OHT 1.25 0.55-2.82 
Cardiomyopathy 0.99 0.51-1.93 
PV stenosis 1.25 0.71-2.18 
Genetic Syndrome 0.89 0.56-1.41 
Chronic lung disease 0.91 0.54-1.54 
Renal insufficiency 1.39 0.68-2.85 
Pressors before catheterization  6.88 4.52-10.45 
Vasodilators before catheterization 0.84 0.58-1.21 
Mechanical ventilation 0.93 0.55-1.55 
Cardiothoracic operation in last 30 days 1.23 0.51-2.97 
Intervention performed 1.01 0.58-1.76 
Systemic arterial saturation (increasing by 5%) 0.81 0.74-0.89 
Supplementary Table 1: Generalized estimating equation model estimates of the risk of catastrophic adverse event 
Abbreviations: APAH-CHD pulmonary hypertension associated with congenital heart disease, IPAH  idiopathic pulmonary arterial hypertension, OHT 
orthotopic heart transplantation, PV pulmonary vein   
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 Covariate OR 95% CI 
Age category   
Neonate with prematurity 4.14  1.25-13.75 
Neonate without prematurity 0.78 0.25-2.39 
Infant with prematurity 0.93 0.44-1.96 
Infant without prematurity 1.59 0.94-2.70 
1-8 years 1 n/a 
8-18 years  0.92  0.54-1.57 
>18 years 0.27 0.04-2.04 
Diagnosis   
IPAH  1 n/a 
APAH-CHD 0.87 0.52-1.47 
Status post OHT 0.68 0.29-1.59 
Cardiomyopathy 1.15 0.55-2.43 
PV stenosis 1.32 0.58-2.99 
Genetic Syndrome 0.82  0.46-1.46 
Chronic lung disease 0.91 0.53-1.56 
Renal insufficiency 1.73 0.79-3.80 
Pressors before catheterization 6.73 4.36-10.37 
Vasodilators before catheterization 0.86 0.54-1.35 
Mechanical ventilation 0.88 0.52-1.49 
Cardiothoracic operation in last 30 days 1.30 0.44-3.83 
Intervention performed 1.08 0.66-1.78 
Systemic arterial saturation (increasing by 5%) 0.84 0.76-0.93 
Supplementary Table 2: Sensitivity analysis of risk factors for catastrophic adverse events restricted to the first catheterization during the 
study period for each subject 
Abbreviations: APAH-CHD pulmonary hypertension associated with congenital heart disease, IPAH  idiopathic pulmonary arterial hypertension, OHT 
orthotopic heart transplantation, PV pulmonary vein  
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Covariate OR 95% CI 
Indexed pulmonary vascular resistance (per 1 WU/m2) 1.08 1.05-1.11 
Age category   
Neonate with prematurity 3.06 0.59-15.93 
Neonate without prematurity 0.72 01.6-3.26 
Infant with prematurity 1.14  0.51-2.52 
Infant without prematurity 1.55  0.85-2.83 
1-8 years 1 n/a 
8-18 years  0.56 0.31-1.03 
>18 years 0.24 0.03-1.81 
Diagnosis   
IPAH  1 n/a 
APAH-CHD 1.17 0.64-2.13 
Status post OHT 1.16  0.45-2.95 
Cardiomyopathy 1.92  0.83-4.44 
PV stenosis 1.11 0.43-2.87 
Genetic Syndrome 0.65 0.31-1.35 
Chronic lung disease 0.80 0.44-1.45 
Renal insufficiency 1.75 0.73-4.21 
Pressors before catheterization 6.24 3.84-10.14 
Vasodilators before catheterization 0.89 0.54-1.48 
Mechanical ventilation 0.99 0.56-1.77 
Cardiothoracic operation in last 30 days 1.87 0.62-5.67 
Intervention performed 1.59 0.92-2.77 
Systemic arterial saturation (increasing by 5%) 0.85  0.75-0.97 
Supplementary Table 3: Association between indexed pulmonary vascular resistance and risk of catastrophic adverse events 
Abbreviations: APAH-CHD pulmonary hypertension associated with congenital heart disease, IPAH  idiopathic pulmonary arterial hypertension, OHT 
orthotopic heart transplantation, PV pulmonary vein, WU Woods Unit  
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 Covariate OR 95% CI 
Mean pulmonary artery pressure (per 10 mmHg)  1.21 1.11-1.32 
Age category   
Neonate with prematurity 5.92 1.72-20.39 
Neonate without prematurity 0.96 0.31-2.96 
Infant with prematurity 0.99  0.45-2.18 
Infant without prematurity 2.07  1.22-3.51 
1-8 years 1 n/a 
8-18 years  0.87 0.50-1.53 
>18 years 0.25 0.04-2.29 
Diagnosis   
IPAH  1 n/a 
APAH-CHD 0.86  0.50-1.49 
Status post OHT 1.23  0.53-2.84 
Cardiomyopathy 1.98 0.92-4.26 
PV stenosis 0.88 0.37-2.08 
Genetic Syndrome 0.99 0.56-1.75 
Chronic lung disease 0.91 0.52-1.59 
Renal insufficiency 1.50 0.68-3.32 
Pressors before catheterization 6.19 3.97-9.66 
Vasodilators before catheterization 0.68 0.42-1.10 
Mechanical ventilation 0.97 0.58-1.63 
Cardiothoracic operation in last 30 days 1.23 0.41-3.69 
Intervention performed 1.16 0.70-1.91 
Systemic arterial saturation (increasing by 5%) 0.85  0.76-0.94 
Supplementary Table 4: Association between mean pulmonary artery pressure and risk of catastrophic adverse events 
Abbreviations: APAH-CHD pulmonary hypertension associated with congenital heart disease, IPAH  idiopathic pulmonary arterial hypertension, OHT 
orthotopic heart transplantation, PV pulmonary vein 
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Covariate OR 95% CI 
Cardiac index (per L/min/sqm)  0.75 0.63-0.90 
Age category   
Neonate with prematurity 3.30 0.84-13.03 
Neonate without prematurity 0.69 0.20-2.45 
Infant with prematurity 1.01  0.49-2.08 
Infant without prematurity 1.24 0.71-2.17 
1-8 years 1 n/a 
8-18 years  0.66 0.37-1.17 
>18 years 0.21 0.03-1.62 
Diagnosis   
IPAH  1 n/a 
APAH-CHD 0.77 0.45-1.32 
Status post OHT 0.63  0.27-1.45 
Cardiomyopathy 0.91 0.42-1.99 
PV stenosis 0.95 0.40-2.24 
Genetic Syndrome 0.71 0.38-1.33 
Chronic lung disease 0.85 0.49-1.47 
Renal insufficiency 1.79 0.81-3.98 
Pressors before catheterization 6.83 4.34-10.74 
Vasodilators before catheterization 0.72 0.44-1.16 
Mechanical ventilation 0.99 0.59-1.68 
Cardiothoracic operation in last 30 days 1.30 0.44-3.88 
Intervention performed 1.39 0.82-2.35 
Systemic arterial saturation (increasing by 5%) 0.76  0.68-0.84 
Supplementary Table 5: Association between cardiac index and risk of catastrophic adverse events 
Abbreviations: APAH-CHD pulmonary hypertension associated with congenital heart disease, IPAH  idiopathic pulmonary arterial hypertension, OHT 
orthotopic heart transplantation, PV pulmonary vein   
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 Covariate OR 95% CI 
Annual PH catheterization volume (per 10 cases)  0.84 0.75-0.94 
Annual catheterization volume (per 50 cases) 1.16 1.04-1.30 
Age category   
Neonate with prematurity 3.10  0.60-16.08 
Neonate without prematurity 0.71 0.16-3.20 
Infant with prematurity 1.14 0.52-2.53 
Infant without prematurity 1.49 0.82-2.72 
1-8 years 1 n/a 
8-18 years  0.56 0.30-1.02 
>18 years 0.23 0.03-1.75 
Diagnosis   
IPAH  1 n/a 
APAH-CHD 1.17 0.64-2.13 
Status post OHT 1.16  0.46-2.94 
Cardiomyopathy 1.95 0.84-4.50 
PV stenosis 1.16 0.45-2.99 
Indexed pulmonary vascular resistance (per 1 WU/sqm)  1.08 1.05-1.11 
Genetic Syndrome 0.65 0.31-1.34 
Chronic lung disease 0.78 0.43-1.40 
Renal insufficiency 1.69 0.70-4.07 
Pressors before catheterization 6.48 4.00-10.50 
Vasodilators before catheterization 0.88 0.53-1.45 
Mechanical ventilation 1.02 0.57-1.82 
Cardiothoracic operation in last 30 days 1.84 0.51-5.53 
Intervention performed 1.64 0.95-2.83 
Systemic arterial saturation (increasing by 5%) 0.86 0.76-0.97 
Supplementary Table 6: Association between total annual catheterization volume and pulmonary hypertension case volume and risk of 
catastrophic adverse events 
Abbreviations: APAH-CHD pulmonary hypertension associated with congenital heart disease, IPAH  idiopathic pulmonary arterial hypertension, OHT 
orthotopic heart transplantation, PV pulmonary vein    by guest on M
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Covariate OR 95% CI 
Annual PH catheterization volume (per 10 cases)  0.89 0.82-0.97 
Annual catheterization volume (per 50 cases) 1.11 1.01-1.22 
Age category   
Neonate with prematurity 3.87  1.18-12.75 
Neonate without prematurity 0.70 0.23-2.13 
Infant with prematurity 1.12 0.57-2.21 
Infant without prematurity 1.68 1.02-2.77 
1-8 years 1 n/a 
8-18 years  0.81 0.48-1.38 
>18 years 0.24 0.03-1.81 
Diagnosis   
IPAH  1 n/a 
APAH-CHD 0.79  0.48-1.29 
Status post OHT 0.73  0.31-1.59 
Cardiomyopathy 1.25  0.62-2.52 
PV stenosis 1.18 0.54-2.61 
Genetic Syndrome 0.88 0.51-1.51 
Chronic lung disease 0.86 0.52-1.44 
Renal insufficiency 1.39 0.64-3.06 
Pressors before catheterization 7.44 4.92-11.26 
Vasodilators before catheterization 0.74 0.48-1.15 
Mechanical ventilation 0.90 0.55-1.46 
Cardiothoracic operation in last 30 days 1.12 0.38-3.27 
Intervention performed 1.09 0.68-1.74 
Systemic arterial saturation (increasing by 5%) 0.82 0.74-0.90 
Supplementary Table 7: Association between total annual catheterization volume and pulmonary hypertension case volume and risk of 
catastrophic adverse events (PVRI removed from the model) 
Abbreviations: APAH-CHD pulmonary hypertension associated with congenital heart disease, IPAH  idiopathic pulmonary arterial hypertension, OHT 
orthotopic heart transplantation, PV pulmonary vein 
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